Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately. We will assess IVC dynamics, LV systolic function \[LV ejection fraction (EF) \& cardiac output (CO)\], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and ACLF with hepatorenal syndrome-acute kidney injury (HRS-AKI).
Study Type
OBSERVATIONAL
Enrollment
75
POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin
PGIMER
Chandigarh, National Capital Territory of Delhi, India
Cardiac output measurement by echocardiography
Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0 and 48 hours after enrollment. The cardiac output at 7 days after enrollment will also be documented. he Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000
Time frame: Day 0, Day 2, Day 7.
IVC size and collapsibility changes
IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
Time frame: Day 0.
IVC size and collapsibility changes
IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
Time frame: Day 2
IVC size and collapsibility changes
IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
Time frame: Day 7.
Number of patients with Complete Response in HRS-AKI
Complete response is defined as a reversal in AKI with a final serum Creatinine (sCr) value of ≤ 0.3 mg/dL of the baseline.
Time frame: Day 7
Number of patients with Partial Response in HRS-AKI
Partial response is defined as regression in the stage of AKI with a final sCr \> 0.3 mg/dL above the baseline.
Time frame: Day 7
Number of patients with Non-Response in HRS-AKI
Non-responder is defined if the sCr did not decrease or increased from the baseline.
Time frame: Day 7
Change in Cystatin C and Neutrophil gelatinase associated lipocalin (NGAL) level
Time frame: Day 0 and Day 7
Change in NT Pro brain natriuretic peptide (BNP) level
Time frame: Day 0 and Day 7
Change in plasma renin activity level
Time frame: Day 0 and Day 7
Change in Galectin-3 level
Time frame: Day 0 and Day 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.